Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Lercadip
2. Lercanidipine Hydrochloride
3. Lerdip
4. Methyl-1,1-dimethyl-2-(n-(3,3-diphenylpropyl)-n-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
5. Rec 15-2375
6. Rec-15-2375
7. Zanidip
1. 100427-26-7
2. Lercanidipine [inn]
3. Lercanil
4. Lercanidipine (inn)
5. V7xtj4r0bh
6. Masnidipine
7. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl Ester
8. 5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
9. 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl Methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
10. 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
11. 3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
12. Lercanil (tn)
13. Ncgc00167492-01
14. Unii-v7xtj4r0bh
15. Lercanidipine [inn:ban]
16. Lercanadipine
17. 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] Ester O3-methyl Ester
18. Lercanidipine [mi]
19. Schembl25268
20. Lercanidipine [who-dd]
21. Chembl250270
22. Schembl6846222
23. Dtxsid2048327
24. Chebi:135930
25. Hms3604g05
26. Bcp21318
27. Hy-b0612
28. Bbl029074
29. S5861
30. Stk639861
31. Akos005571238
32. Db00528
33. Sdccgsbi-0633690.p001
34. Ncgc00167492-02
35. Ncgc00167492-11
36. (+-)-2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
37. Ac-15409
38. As-75252
39. Ft-0631006
40. C13971
41. D08111
42. 427l267
43. A800200
44. A929939
45. Q410492
46. Sr-01000884000
47. Sr-01000884000-1
48. [2-oxo-3-(3-trifluoromethyl-phenoxy)-propyl]-phosphonic
49. 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl (4rs)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
50. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl Ester
51. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl Methyl Ester
52. O5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] O3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| Molecular Weight | 611.7 g/mol |
|---|---|
| Molecular Formula | C36H41N3O6 |
| XLogP3 | 6.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 13 |
| Exact Mass | 611.29953604 g/mol |
| Monoisotopic Mass | 611.29953604 g/mol |
| Topological Polar Surface Area | 114 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1090 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Lercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
C08CA13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C08 - Calcium channel blockers
C08C - Selective calcium channel blockers with mainly vascular effects
C08CA - Dihydropyridine derivatives
C08CA13 - Lercanidipine
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 81666-007
Start Marketing Date : 2025-01-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0099
Start Marketing Date : 2013-12-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0136
Start Marketing Date : 2004-06-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name : Lercanidipine
Dosage Form : DC Granules
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : DC Granules
Dosage Strength : 10MG
Brand Name : Lercanidipine
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Enalapril; lercanidipine hydrochloride
Brand Name :
Dosage Form : Tablet
Dosage Strength : 10; 10
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Enalapril; lercanidipine hydrochloride
Dosage : Tablet
Dosage Strength : 10; 10
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Enalapril; lercanidipine hydrochloride
Brand Name :
Dosage Form : Tablet
Dosage Strength : 20MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Enalapril; lercanidipine hydrochloride
Dosage : Tablet
Dosage Strength : 20MG; 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Russia
Brand Name :
Dosage Form : Film-Coated Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Russia
Packaging :
Regulatory Info :
Dosage : Film-Coated Tablet
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Russia
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : DC Granules
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : DC Granules
Dosage Strength : 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic CTD, BE- Available
Registration Country : Jordan
Brand Name :
Dosage Form : TABLET
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic CTD, BE- Available
Registration Country : Jordan
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : Tablet
Dosage Strength :
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Lercanidipine Hydrochloride; Enalapril
Brand Name :
Dosage Form : Tablet
Dosage Strength : 10MG; 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Lercanidipine Hydrochloride; Enalapril
Dosage : Tablet
Dosage Strength : 10MG; 10MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Lercanidipine Hydrochloride; Enalapril
Brand Name :
Dosage Form : Tablet
Dosage Strength : 10MG; 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Lercanidipine Hydrochloride; Enalapril
Dosage : Tablet
Dosage Strength : 10MG; 20MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Lercanidipine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lercanidipine manufacturer or Lercanidipine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lercanidipine manufacturer or Lercanidipine supplier.
PharmaCompass also assists you with knowing the Lercanidipine API Price utilized in the formulation of products. Lercanidipine API Price is not always fixed or binding as the Lercanidipine Price is obtained through a variety of data sources. The Lercanidipine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lercanil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lercanil, including repackagers and relabelers. The FDA regulates Lercanil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lercanil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lercanil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lercanil supplier is an individual or a company that provides Lercanil active pharmaceutical ingredient (API) or Lercanil finished formulations upon request. The Lercanil suppliers may include Lercanil API manufacturers, exporters, distributors and traders.
click here to find a list of Lercanil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lercanil DMF (Drug Master File) is a document detailing the whole manufacturing process of Lercanil active pharmaceutical ingredient (API) in detail. Different forms of Lercanil DMFs exist exist since differing nations have different regulations, such as Lercanil USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lercanil DMF submitted to regulatory agencies in the US is known as a USDMF. Lercanil USDMF includes data on Lercanil's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lercanil USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lercanil suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lercanil Drug Master File in Korea (Lercanil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lercanil. The MFDS reviews the Lercanil KDMF as part of the drug registration process and uses the information provided in the Lercanil KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lercanil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lercanil API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lercanil suppliers with KDMF on PharmaCompass.
A Lercanil written confirmation (Lercanil WC) is an official document issued by a regulatory agency to a Lercanil manufacturer, verifying that the manufacturing facility of a Lercanil active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lercanil APIs or Lercanil finished pharmaceutical products to another nation, regulatory agencies frequently require a Lercanil WC (written confirmation) as part of the regulatory process.
click here to find a list of Lercanil suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lercanil as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lercanil API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lercanil as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lercanil and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lercanil NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lercanil suppliers with NDC on PharmaCompass.
Lercanil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lercanil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lercanil GMP manufacturer or Lercanil GMP API supplier for your needs.
A Lercanil CoA (Certificate of Analysis) is a formal document that attests to Lercanil's compliance with Lercanil specifications and serves as a tool for batch-level quality control.
Lercanil CoA mostly includes findings from lab analyses of a specific batch. For each Lercanil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lercanil may be tested according to a variety of international standards, such as European Pharmacopoeia (Lercanil EP), Lercanil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lercanil USP).
